Clinical trials: Population Medicine
High Risk MC4R Genotype, Low Risk MC4R Genotype
1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain
We will conduct a 12-week, randomized open label study, comparing usual care (UC) antipsychotic treatment (aripiprazole, quetiapine, risperidone) with ziprasidone (ZIP) in children and adolescents aged 13-18 years old.
- Conditions
- High Risk MC4R Genotype, Low Risk MC4R Genotype, One Week or Less Antipsychotic Lifetime Exposure
- Trial name
- NCT01844700
- Testing
- Ziprasidone, aripiprazole, quetiapine, or risperidone
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Northwell Health
HIV, AIDS
Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations
Specific Aim: To conduct a randomized, placebo-controlled trial of extended release-naltrexone (XR-NTX) among Human Immunodeficiency Virus (HIV) infected prisoners meeting Diagnostic Statistical Manual IV (DSM-IV) criteria for…
- Conditions
- HIV, AIDS, Opioid Dependence, Drug Dependence
- Trial name
- NewHope (NCT01246401)
- Testing
- Extended-Release Naltrexone
- Where
- 3 sites in United States
- Volunteers
- 151 people, healthy volunteers welcome
- Sponsor
- Yale University
Bronchial Asthma, Genome Wide Association Studies
The Role of Genetic Factors in the Development of Bronchial Asthma in the Kazakh Population
To research for a genetic marker of bronchial asthma, a single nucleotide polymorphism (SNP) analysis of DNA obtained from the peripheral blood of patients with bronchial asthma and normal control will be performed.
- Trial name
- NCT05088512
- Testing
- SNP analysis of the DNA
- Where
- Kazakhstan
- Volunteers
- 300 people
- Sponsor
- Asfendiyarov Kazakh National Medical University
Constipation
Lubiprostone for Chronic Idiopathic Constipation Treatment
The purpose of this study is to evaluate the efficacy and safety of oral administration of 24 ug of lubiprostone twice daily (BID) for 4 weeks in participants with chronic idiopathic constipation (CIC) compared with placebo.
- Trial name
- NCT02729909
- Testing
- Lubiprostone
- Where
- 10 sites in Mexico
- Volunteers
- 211 people
- Sponsor
- Takeda
HIV
Polypharmacy and Clinically Significant Drug Interactions Among HIV-Infected Patients Receiving Antiretroviral Therapy
This will be a cross-sectional population-based study carried out in the region of Madrid (6,468,322 inhabitants according to current census) to quantify the number of Co-meds in HIV-infected individuals on ART in the region of…
- Trial name
- PODIUM (NCT03123575)
- Volunteers
- 1,000 people
- Sponsor
- Hospital General Universitario Gregorio Marañon
Spine Surgery, Reversal of Neuromuscular Blockade
Sugammadex vs Neostigmine/Glycopyrrolate on Urinary Retention After Spine Surgery
This is an active-comparator controlled study to evaluate the effect of sugammadex compared to neostigmine/glycopyrrolate for reversal of rocuronium on the incidence of urinary retention after subjects undergo elective ambulatory…
- Conditions
- Spine Surgery, Reversal of Neuromuscular Blockade, Urinary Retention Postoperative
- Trial name
- NCT05887375
- Testing
- Sugammadex, Neostigmine, Glycopyrrolate
- Where
- United States
- Volunteers
- 118 people
- Sponsor
- University of Missouri-Columbia
Urinary Bladder, Overactive
A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug
Solifenacin succinate as a tablet formulation is already on the market for the treatment of symptoms of overactive bladder in adults.
- Trial name
- LION (NCT01565707)
- Testing
- Solifenacin Succinate Suspension, Urotherapy
- Where
- 46 sites in United States, Belgium and 14 more
- Volunteers
- 189 people
- Sponsor
- Astellas Pharma Europe B.V.
Rheumatoid Arthritis
A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products
The objective of the current study is to assess the immunogenicity and safety of transitioning subjects with RA to DRL_RI from US-rituximab/EU-rituximab to continued treatment with US-rituximab/EU-rituximab.
- Trial name
- RI-01-007 (NCT04268771)
- Testing
- Experimental: Arm A: DRL_RI, Arm B: Rituxan®/Mabthera®
- Where
- 26 sites in United States
- Volunteers
- 140 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Hypertension, Resistant Hypertension
A Phase II Study of VB19055 in Uncontrolled or Resistant Hypertension
A multicenter, randomized, double-blind, placebo-controlled, dose-ranging Phase II trial of VB19055 for 12 weeks in 240 adults with uncontrolled hypertension (including resistant hypertension).
- Conditions
- Hypertension, Resistant Hypertension, Uncontrolled Hypertension
- Trial name
- NCT07833098
- Testing
- VB19055 Dose A QD, VB19055 Dose B QD, VB19055 Dose C QD
- Where
- 24 sites in China
- Volunteers
- 240 people
- Sponsor
- Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis
National Registry of Rare Kidney Diseases
The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research.
- Conditions
- Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis, AHL Amyloidosis, AL Amyloidosis
- Trial name
- RaDaR (NCT06065852)
- Where
- United Kingdom
- Volunteers
- 35,000 people
- Sponsor
- UK Kidney Association
Dyskinesias, Drug-induced
Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
This study will assess the safety, tolerability and efficacy of AQW051 in treating moderate to severe L-dopa induced dyskinesias (movement disorders) in patients with Parkinson's disease.
- Trial name
- NCT01474421
- Testing
- AQW051
- Where
- 24 sites in United States, France and 2 more
- Volunteers
- 71 people
- Sponsor
- Novartis Pharmaceuticals
Bipolar Disorder, Suicide
MAPS Group Therapy Model for Bipolar Disorder
This study aims to develop the MAPS(M,Monitoring;A,Assessing;P,Preventing or Reducing Relapse;S,Smart goal setting) group therapy model for bipolar disorder patients as other adjuvant clinical treatment and develop the…
- Trial name
- NCT01152034
- Testing
- psychoeducation group therapy
- Where
- Taiwan
- Volunteers
- 68 people
- Sponsor
- Mackay Memorial Hospital
Anesthesia, Local, Anesthesia
Prediction Models for Cardiovascular and Neurocognitive Disease Risk in the General Population
More accurate and earlier identification of people at risk of cardiovascular disease (CVD) and neurodegenerative diseases (memory, cognition, dementia) through the appropriate use of biomarkers could lead to earlier initiation of…
- Trial name
- CME (NCT05951764)
- Testing
- Non-invasive measurement of arterial stiffness by Pulse Wave Velocity (PWV)
- Where
- France
- Volunteers
- 396 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Diabetic Macular Edema
Suprachoroidal Sustained-Release OXU-001 Compared to Intravitreal Ozurdex® in the Treatment of Diabetic Macular Edema
The purpose of this clinical trial is to compare safety, tolerability, efficacy, and durability of two dose levels of suprachoroidal sustained-release OXU-001 (dexamethasone microspheres; DEXAspheres®) using the Oxulumis®…
- Trial name
- OXEYE (NCT05697809)
- Testing
- OXU-001, Semi-automated suprachoroidal illuminated microcatheter, Ozurdex® Ophthalmic Intravitreal Implant
- Where
- 9 sites in United States, Puerto Rico
- Volunteers
- 3 people
- Sponsor
- Oxular Limited
Prostate Cancer With at Least One Bone Lesion in Patients Receiving Hormonal Therapy and Treatment With Bisphosphonates is Indicated
A Study to Evaluate the Efficacy and Tolerability of Zoledronic Acid in Patients With Metastatic Prostate Cancer Who Can be Treated With a Group of Medications Known as Bisphosphonates
The purpose of this study is to assess the efficacy and tolerability of zoledronic acid in preventing skeletal-related events in patients with prostate cancer
- Trial name
- NCT00172016
- Testing
- Zoledronic acid
- Volunteers
- 43 people
- Sponsor
- Novartis Pharmaceuticals
Infertility
Efficacy and Safety of Crinone Versus Combination Medication (ACCESS)
The study to compare to the efficacy and safety of Crinone versus combination medication in infertile women receive frozen-thawed embryo transfer (FET) in artificial cycles (AC).
- Trial name
- NCT03858049
- Testing
- Crinone, Duphaston
- Where
- China
- Volunteers
- 172 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Psychotic Disorders, Schizophrenia
Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants
The purpose of this study is to gather information about the steady-state plasma concentrations of aripiprazole, olanzapine, quetiapine and their relevant metabolites, at various dose levels and at different time points after…
- Conditions
- Psychotic Disorders, Schizophrenia, Bipolar Disorder, Depressive Disorder
- Trial name
- NCT02087579
- Testing
- Aripiprazole, oral formulation, Olanzapine, oral formulation, Paliperidone, oral formulation
- Where
- 24 sites in United States, Argentina and 5 more
- Volunteers
- 305 people
- Sponsor
- Janssen Research & Development, LLC
Adult Growth Hormone Deficiency
Study of an Extended-Release, Crystalline Formulation of Recombinant Human Growth Hormone (ALTU-238) in Growth Hormone Deficient Adults to Determine Pharmacokinetics, Pharmacodynamics, and Drug Safety
ALTU-238 is a long acting crystalline formulation of recombinant human growth hormone (rhGH) that is being developed for the treatment of growth hormone deficiency in adults and children.
- Trial name
- NCT00297713
- Testing
- ALTU-238
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Altus Pharmaceuticals
Asthma
Bioequivalence With Clinical Endpoint Study of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma
Τherapeutic equivalence, randomized, multiple-dose, placebo-controlled, observer-blind, parallel group design consisting of a 2-week run-in period followed by a 4-week treatment period with Fluticasone propionate 100 mcg and…
- Trial name
- AERO-PD (NCT05664061)
- Testing
- Fluticasone Propionate 100 mcg and Salmeterol 50 mcg inhalation Powder/Respirent Pharmaceuticals, ADVAIR DISKUS® 100/50 mcg inhalation powder pre-dispensed/GSK
- Where
- Greece
- Volunteers
- 451 people
- Sponsor
- Respirent Pharmaceuticals Co Ltd.
Weight Loss, Diabetes Mellitus, Type 2
Reducing Weight and Diabetes Risk in an Underserved Population (STRIDE)
The purpose of this study is to examine the effectiveness of a lifestyle intervention designed to reduce weight and diabetes risk in a population of individuals with mental illness who are also taking antipsychotic medications.
- Conditions
- Weight Loss, Diabetes Mellitus, Type 2, Psychotic Disorders
- Trial name
- STRIDE (NCT00790517)
- Testing
- Premier Lifestyle Intervention with DASH Diet
- Where
- 3 sites in United States
- Volunteers
- 200 people
- Sponsor
- Kaiser Permanente
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.